A non-interface self-assembled microcapsule and its preparation method and application
By using a combination technology of polymer chelating agents, metal ions and perfluorocarbons in the preparation of microcapsules, non-interface self-assembled microcapsules are formed, which solves the problems of inactivation of biologically active substances and difficulty in interface self-assembly, and achieves biosafety , preparation of microcapsules with uniform particle size has expanded its possibility of application in biomedical science.
Patent Information
- Application Number
- CN202211286688.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-20
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-10-20
AI Technical Summary
The organic solvents used in the existing microcapsule preparation technology will inactivate the biologically active substances and make it difficult to form non-interface self-assembled microcapsules, limiting their widespread use in biomedical science.
After mixing polymer chelating agent with co-solvent, chelating with metal ions, transfer to perfluorocarbon solvent to shake to form gel microspheres, and then transfer to aqueous solution containing lipid molecules to shake to remove perfluorocarbon compounds to obtain Non-interface self-assembled microcapsules.
The payload and protection of biologically active substances are achieved, and non-interface self-assembled microcapsules with uniform particle size and biosafety have a wide range of biomedical application prospects, especially in tumor immunotherapy, drug transport and mRNA vaccines.
Smart Images

Figure CN115919795B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of micro-nano particle preparation, in particular to a self-assembling microcapsule and a preparation method and application thereof. Background Art
[0002] Microcapsules are microcapsules with solid or liquid cores wrapped by capsule materials. They are usually formed by self-assembly of fatty acids, proteins, inorganic nanoparticles, polymers and other components, and are used for the synthesis, regulation and transport of biomolecules. As a new type of biofunctional material, self-assembled microcapsules have broad application prospects.
[0003] Microcapsules can deliver drugs or bioactive substances to treat diseases. However, the organic solvents used in the preparation of microcapsules can inactivate bioactive substances. Perfluorocarbons are non-toxic to bioactive substances. They can be used as blood substitutes and as adjuvants for a variety of oxygen-demanding therapies. They are widely used in the treatment of cardiovascular and lung diseases. They can be used for adjuvant treatment of burns and tumor radiotherapy and chemotherapy, and can also be used as carriers of drugs and contrast agents. They have a very wide range of application value in clinical treatment. They are also ideal solvents for preparing microcapsules, but they are very inert and cannot be emulsified with water. Because liquid substances can reshape the morphology of solid substances through scouring, even if there is no emulsification, for example, running water can scour stones into pebbles. We found that even if there is no stable interface between the two phases, spherical structures can still be formed under controlled conditions. Inspired by the ubiquitous spherical objects in nature, we developed a method for preparing non-interface self-assembled microcapsules, using perfluorocarbons to repeatedly scour organic gels to form gel microspheres, and then wrapping lipid molecules in the gel microspheres to prepare microcapsules. Therefore, those skilled in the art are committed to developing a method for preparing non-interfacial self-assembled microcapsules, by which microcapsules loaded with bioactive substances are prepared.
[0004] However, there is no report on the preparation of non-interfacial self-assembled microcapsules using the method of the present application. Summary of the invention
[0005] In view of the defects in the traditional microcapsule preparation technology, the first object of the present invention is to provide a method for preparing non-interfacial self-assembled capsules.
[0006] The second object of the present invention is to provide a method for preparing non-interface self-assembled microcapsules loaded with bioactive substances.
[0007] The third object of the present invention is to provide a non-interface self-assembled microcapsule.
[0008] To achieve the first purpose, the technical solution adopted by the present invention is:
[0009] A method for preparing a non-interface self-assembled microcapsule is provided. In a specific embodiment, the method comprises the following steps:
[0010] (a) dissolving a polymer chelating agent and a cosolvent in an organic solvent, heating and shaking until they are completely dispersed;
[0011] (b) mixing the cooled organic solvent with the gel-forming macromolecules;
[0012] (c) after mixing, transferring to a solution containing metal ions for chelation to obtain a viscous colloid; characterized in that it also includes the steps of:
[0013] (d) transferring the viscous colloid into a perfluorocarbon solvent and shaking at room temperature until a uniform emulsion is formed to obtain gel microspheres;
[0014] (e) transferring the gel microspheres into an aqueous solution containing lipid molecules and shaking to obtain lipid gel microspheres;
[0015] (f) Non-interfacial self-assembled microcapsules were obtained by removing perfluorocarbon compounds from lipid gel microspheres.
[0016] Furthermore, the perfluorocarbon compound in step (d) is one or more of perfluoroalkanes such as perfluorohexane, perfluorocyclohexane, perfluoroheptane, etc., perfluoroalkylcarboxylic acids such as perfluorobutyric acid, perfluorooctanoic acid, tridecafluoroheptanoic acid, etc., perfluoroalkylamines such as perfluorotriethylamine, etc., perfluorohalogenated alkanes such as 1-bromoheptafluorooctane, perfluorohexyl bromide, etc., and 3M fluorinated liquid FC-40.
[0017] Furthermore, the lipid molecules in step (e) are one or more of phosphatidylglycerol phospholipids, phosphatidylcholine phospholipids, phosphatidylserine phospholipids, 1-palmitoyl-2-stearoyl phosphatidylcholine, phosphatidylethanolamine phospholipids, glycerophosphatidic acid phospholipids, soybean lecithin, lysophospholipids, 1,2-dioleoyloxy-3-(dimethylamino)propane, 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine, (2,3-dioleoyl-propyl)-trimethylamine, red blood cell membrane and tumor cell membrane.
[0018] Furthermore, the polymer chelating agent in step (a) is one or more of polyvinyl alcohol (PVA), polyacrylic acid (PAA), heparin, dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol-diethylenetriaminepentaacetic acid (DPPE-PEG-DTPA), distearoylphosphatidylethanolamine-polyethylene glycol-diethylenetriaminepentaacetic acid (DSPE-PEG-DTPA), dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol-ethylenediaminetetraacetic acid (DPPE-PEG-EDTA), and distearoylphosphatidylethanolamine-polyethylene glycol-ethylenediaminetetraacetic acid (DSPE-PEG-EDTA).
[0019] Furthermore, the cosolvent in step (a) is one or more of disodium lauryl sulfosuccinate (DLS), disodium fatty alcohol polyoxyethylene ether (3) sulfosuccinate (MES), disodium coconut oil monoethanolamide sulfosuccinate (DMSS), SPAN, monolauryl phosphate (MAP), Tween (TWEEN), potassium monododecyl phosphate (MAPK), potassium lauryl ether phosphate (MAEPK), coconut oil monoethanolamide (CMEA), and polyethoxylated castor oil (EL).
[0020] Furthermore, the macromolecules capable of forming a gel in step (b) are one or more of agarose, polyacrylamide, alginate, hyaluronic acid, hydroxyethyl methacrylate, poly (N-isopropylacrylamide), chitosan, and matrigel.
[0021] Furthermore, the metal ions in step (c) are one or more of calcium ions, magnesium ions, sodium ions, potassium ions, and iron ions.
[0022] To achieve the second purpose of the present invention, the technical solution adopted by the present invention is:
[0023] A method for preparing non-interface self-assembled microcapsules loaded with bioactive substances, further comprising the following steps:
[0024] (g) adding a biologically active substance to the mixture obtained in step (a);
[0025] (h) mixing the self-assembled microcapsules obtained in step (f) or (g) with the gene.
[0026] Furthermore, the bioactive substance is a chemical drug or a gene or a biological macromolecule, and the gene in step (h) is one or more of a plasmid, siRNA, microRNA, piRNA, circleRNA and lncRNA.
[0027] To achieve the third object of the present invention, the technical solution adopted by the present invention is:
[0028] A non-interface self-assembled microcapsule is prepared by any one of the above methods.
[0029] The advantages of the present invention are:
[0030] The method provided by the present invention firstly mixes a polymer chelating agent, a cosolvent and a macromolecule capable of forming a gel, then chelates with metal ions, and then transfers to a perfluorocarbon compound solvent and repeatedly shakes to obtain gel microspheres, and then transfers to an aqueous solution containing lipid molecules, shakes to obtain lipid gel microspheres, and finally removes the perfluorocarbon compounds in the lipid gel microspheres to obtain non-interface self-assembled microcapsules. Perfluorocarbon compounds have very good biosafety and will not affect the activity of biologically active substances, so that the microcapsules have very wide biomedical application value. Chemical drugs, genes, and biological macromolecules can be added during the preparation process of the self-assembled microcapsules to obtain self-assembled microcapsules loaded with chemical drugs, genes or biological macromolecules. The lipid molecules on the surface of the microcapsules have a structure similar to that of the cell membrane, so that they can transport the substances they carry into the cells through membrane fusion.
[0031] The preparation method provided by the present invention is simple, efficient, green and environmentally friendly, with high yield. The prepared microcapsules have uniform particle size of about 10-100 μm, and have broad application prospects in tumor immunotherapy, drug delivery, and mRNA vaccines.
[0032] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Attached Figure 1 This is a microscope photograph of a preferred embodiment of the present invention in which gel microspheres are dispersed in a perfluorinated compound;
[0034] Attached Figure 2 is a microscope photograph of a non-interface self-assembled microcapsule of a preferred embodiment of the present invention;
[0035] Attached Figure 3 It is a schematic diagram of the preparation process of non-interfacial self-assembled microcapsules according to a preferred embodiment of the present invention;
[0036] Attached Figure 4 This is a Q-PCR result diagram of knocking down the drug resistance gene MDR1 of the non-interface self-assembled microcapsule of a preferred embodiment of the present invention;
[0037] Attached Figure 5 This is a Q-PCR result diagram of knocking down the drug resistance gene MDR1 of the non-interface self-assembled microcapsule of a preferred embodiment of the present invention;
[0038] Attached Figure 6 This is a Q-PCR result diagram of knocking down the drug resistance gene MDR1 of the non-interface self-assembled microcapsule of a preferred embodiment of the present invention;
[0039] Attached Figure 7It is an agarose gel electrophoresis diagram of mRNA transcribed by non-interface self-assembled microcapsules in a preferred embodiment of the present invention;
[0040] Attached Figure 8 It is a preferred embodiment of the present invention wherein the non-interface self-assembled microcapsules knock down the drug resistance gene MDR1 and the half inhibitory concentration (IC50) of cells to paclitaxel;
[0041] Attached Fig. 9 It is a preferred embodiment of the present invention that the non-interface self-assembled microcapsules knock down the drug-resistant gene MDR1 and the half-inhibitory concentration (IC50) of cells to paclitaxel. DETAILED DESCRIPTION
[0042] The technical content of the present invention is further described below in conjunction with the examples: The following examples are illustrative, not restrictive, and the protection scope of the present invention cannot be limited by the following examples. The test methods used in the following examples are usually based on conventional conditions or conditions recommended by the manufacturer unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0043] The preparation process of the non-interfacial self-assembled microcapsules shown in the following examples is as shown in the attached Figure 3 As shown, firstly, a polymer chelating agent, a cosolvent and a macromolecule capable of forming a gel are mixed, and after chelating with metal ions, they are transferred to a perfluorocarbon compound solvent, and after repeated shaking, gel microspheres are obtained, and then transferred to an aqueous solution containing lipid molecules, and shaken to obtain lipid gel microspheres, and finally the perfluorocarbon compounds in the lipid gel microspheres are removed to obtain non-interface self-assembled microcapsules. Chemical drugs, genes, and biological macromolecules can be added during the preparation process of the self-assembled microcapsules to obtain self-assembled microcapsules loaded with chemical drugs, genes or biological macromolecules.
[0044] It should be noted that, due to formatting issues, the siRNA involved in the embodiment needs to replace the sixteenth, eighteenth, and U in SEQ ID NO: 1 with T in the sequence table, and the original sequence is: GGAAAAGAAACCAACUGUCTT. The six, eight, ten, eleven, twelve, fourteen, fifteen, sixteen, and seventeenth U in SEQ ID NO: 2 are replaced with T, and the original sequence is: GACAGUUGGUUUCUUUUUCCTT.
[0045] Example 1: Preparation of non-interfacial self-assembled microcapsules
[0046] 800 mg of DSPE-PEG-EDTA and 10 μL of Tween were dissolved in 1 mL of ethanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 1.5 mL of Matrigel, and then 5 mL of magnesium chloride solution (60 mg / mL) was added. The mixture was then transferred to 40 mL of perfluorohexyl bromide and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The perfluorohexyl bromide solution was then transferred to an aqueous solution containing 10 mg / mL 1,2-dioleoyloxy-3-(dimethylamino)propane and 10 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing the perfluorohexyl bromide, self-assembled microcapsules were obtained, which were regular spherical structures with a particle size of about 10-70 nanometers under microscopic observation.
[0047] Example 2: Preparation of non-interfacial self-assembled microcapsules
[0048] 400 mg of DSPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of ethanol and shaken at 60°C until completely dispersed. After cooling to 4°C, the mixture was mixed with 0.75 mL of Matrigel and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion ( Figure 1 ). Then the 1-bromoheptafluorooctane solution was transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules ( Figure 2 ), and under microscope observation, it is a regular spherical structure with a particle size of about 10-50 nanometers.
[0049] Example 3: Preparation of non-interfacial self-assembled microcapsules
[0050] 400 mg of DPPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of methanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 0.75 mL of Matrigel, and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of perfluorotriethylamine and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The perfluorotriethylamine solution was then transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing the perfluorotriethylamine, self-assembled microcapsules were obtained, which were regular spherical structures with a particle size of about 20-70 nanometers under microscopic observation.
[0051] Example 4: Preparation of non-interfacial self-assembled microcapsules
[0052] 400 mg of DPPE-PEG-DTPA, 200 μL of polyethoxylated castor oil, and 10 mg of doxorubicin were dissolved in 0.5 mL of ethanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 0.75 mL of Matrigel, and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules were obtained, which were regular spherical structures with a particle size of about 10-70 nanometers under microscopic observation.
[0053] Example 5: Preparation of non-interfacial self-assembled microcapsules
[0054] 400 mg of DSPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of ethanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 0.75 mL of Matrigel (containing 50 μg of CREB1 plasmid), and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules were obtained, which were regular spherical structures with a particle size of about 10-100 nanometers under microscopic observation.
[0055] Example 6: Preparation of gene-loaded non-interfacial self-assembled microcapsules
[0056] The self-assembled microcapsules obtained in Example 2 were mixed with small interfering RNA (siRNA-MDR1) of the multidrug resistance gene (MDR1). 5 μL of self-assembled microcapsules (80 mg / mL) and 5 μL of siRNA-MDR1 (20 μM) were mixed and added to paclitaxel-resistant ovarian cancer cells A2780 / PTX (purchased from Nanjing Keygene Biotechnology, #KG635). After 48 hours, the expression level of the drug resistance gene MDR1 was detected by Western blot (primary antibody was rabbit anti-MDR1, secondary antibody was goat anti-rabbit IgG) and real-time fluorescence quantitative PCR (Q-PCR, Sense-1GGAAAAGAAACCAACUGUCTT (SEQ ID NO: 1), Antisense-1GACAGUUGGUUUCUUUUCCTT (SEQ ID NO: 2)). After treatment with the self-assembled microcapsules carrying siRNA-MDR1, the expression level of MDR1 in A2780 / PTX was reduced by more than 80% ( Figure 4 ).
[0057] Example 7: Preparation of non-interfacial self-assembled microcapsules loaded with genes
[0058] The self-assembled microcapsules obtained in Example 2 were mixed with small interfering RNA (siRNA-MDR1) of the multidrug resistance gene (MDR1). 5 μL of self-assembled microcapsules (80 mg / mL) and 5 μL of siRNA-MDR1 (20 μM) were mixed and added to adriamycin-resistant human leukemia cells K562 / ADR (purchased from Nanjing Keygene Biotechnology, #KG301). After 48 hours, the expression level of the drug resistance gene MDR1 was detected by Western blot (primary antibody was rabbit anti-MDR1, secondary antibody was goat anti-rabbit IgG) and real-time fluorescence quantitative PCR (Q-PCR, Sense-1GGAAAAGAAACCAACUGUCTT (SEQ ID NO: 1), Antisense-1GACAGUUGGUUUCUUUUCCTT (SEQ ID NO: 2)). After treatment with the self-assembled microcapsules carrying siRNA-MDR1, the expression level of MDR1 in A2780 / PTX was reduced by more than 80% ( Figure 5 ).
[0059] Example 8: Preparation of non-interfacial self-assembled microcapsules loaded with genes
[0060] The self-assembled microcapsules obtained in Example 3 were mixed with small interfering RNA (siRNA-MDR1) of the multidrug resistance gene (MDR1). 5 μL of self-assembled microcapsules (80 mg / mL) and 5 μL of siRNA-SRI (20 μM) were mixed and added to paclitaxel-resistant ovarian cancer cells SKOV3 / PTX (constructed by the Clinical Medicine Research Center of Jinshan Hospital Affiliated to Fudan University, treasure number: C2014204). After 48 hours, the expression level of the drug resistance gene SRI was detected by Western blot (primary antibody: rabbit anti-MDR1, secondary antibody: goat anti-rabbit IgG) and real-time fluorescence quantitative PCR (Q-PCR, Sense-1 GGAAAAGAAACCAACUGUCTT (SEQ ID NO: 1), Antisense-1 GACAGUUGGUUUCUUUUCCTT (SEQ ID NO: 2)). After treatment with the self-assembled microcapsules loaded with siRNA-SRI, the expression level of SRI in SKOV3 / PTX was reduced by more than 80% ( Figure 6 ).
[0061] Example 9: Preparation of non-interfacial self-assembled microcapsules loaded with biomacromolecules
[0062] 400 mg of DSPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of ethanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 0.75 mL of Matrigel (100 ng of linear DNA fragment of EGFP (enhanced green fluorescent protein) and RNA transcriptase), and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, self-assembled microcapsules were obtained after removing 1-bromoheptafluorooctane.
[0063] The self-assembled microcapsules obtained above were transferred into an aqueous solution containing nucleotides and incubated at 37°C for 4 hours. The mRNA was transcribed in the self-assembled microcapsules. The microcapsules were cleaved with trypsin, and the molecular weight and integrity of the mRNA were identified by agarose gel electrophoresis. The results showed that the mRNA was successfully transcribed ( Figure 7 ).
[0064] Example 10: Preparation of non-interfacial self-assembled microcapsules loaded with biomacromolecules
[0065] 400 μL of polyvinyl alcohol and 10 μL of Tween were dissolved in 0.5 mL of ethanol and shaken until completely dispersed. The mixture was mixed with 0.75 mL of Matrigel (100 ng of linear DNA fragment of EGFP and RNA transcriptase), and then 2.5 mL of magnesium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing 5 mg / mL 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, self-assembled microcapsules were obtained after removing 1-bromoheptafluorooctane.
[0066] The self-assembled microcapsules obtained above were transferred into an aqueous solution containing nucleotides and incubated at 37°C for 4 hours to allow mRNA to be transcribed in the self-assembled microcapsules. The microcapsules were cleaved with trypsin, and the molecular weight and integrity of the mRNA were identified by agarose gel electrophoresis, proving that the mRNA was successfully transcribed.
[0067] Example 11: Preparation of non-interfacial self-assembled microcapsules loaded with genes
[0068] The self-assembled microcapsules obtained in Example 3 were mixed with Fam-siRNA (purchased from Shanghai Jima Biotechnology). 5 μL of self-assembled microcapsules (80 mg / mL) and 5 μL of Fam-siRNA (20 μM) were mixed and added to 293T cells (purchased from ATCC, #CRL-3216). After 4 hours, the cells were digested with trypsin and collected by centrifugation. The endocytosis efficiency of Fam-siRNA was detected by flow cytometry, which proved that the endocytosis efficiency of Fam-siRNA by 293T cells exceeded 99%.
[0069] Example 12: Preparation of non-interfacial self-assembled microcapsules loaded with genes
[0070] The self-assembled microcapsules obtained in Example 3 were mixed with Fam-siRNA (purchased from Shanghai Jima Biotechnology). 5 μL of self-assembled microcapsules (80 mg / mL) and 5 μL of Fam-siRNA (20 μM) were mixed and added to 293T cells (purchased from ATCC, #CRL-3216). After 4 hours, the cells were fixed with paraformaldehyde, the cell nuclei were stained with DAPI, and the distribution of Fam-siRNA in 293T cells was observed under a laser confocal microscope, which showed that Fam-siRNA entered the cells and made the cells appear bright green.
[0071] Example 13: Application of non-interfacial self-assembled microcapsules
[0072] 5 mg of 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine was dissolved in 20 μL of chloroform, and 2.5 μL of Cy5.5-N-hydroxysuccinimide ester (10 mg / mL) in dimethyl sulfoxide (DMSO) was added and reacted for 5 hours to obtain Cy5.5-modified dioleoylphosphatidylethanolamine.
[0073] 400 mg of DSPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of ethanol and shaken at 60 °C until completely dispersed. After cooling to 4 °C, the mixture was mixed with 0.75 mL of Matrigel, and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing 5 mg / mL Cy5.5-modified 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine and 5 mg / mL (2,3-dioleoyl-propyl)-trimethylamine. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules were obtained, which were regular spherical structures with a particle size of about 10-50 nanometers under microscopic observation.
[0074] The Cy5.5-labeled self-assembled microcapsules obtained above were added to 293T cells (purchased from ATCC, #CRL-3216). After 4 hours, the cells were fixed with paraformaldehyde, the cell nuclei were stained with DAPI, and the binding of the self-assembled microcapsules to the 293T cells was observed under a laser confocal microscope, showing that the 293T cells were bright red, proving that the self-assembled microcapsules can bind to the cells well.
[0075] Example 14: Application of non-interfacial self-assembled microcapsules
[0076] The self-assembled microcapsules obtained in Example 9 were added to 293T cells (purchased from ATCC, #CRL-3216). After 24 hours, the cells were fixed with paraformaldehyde, the cell nuclei were stained with DAPI, and the expression of EGFP was observed under a laser confocal microscope. The results showed that 293T cells were bright green, proving that EGFP-mRNA was well expressed in 293T cells.
[0077] Example 15: Application of non-interfacial self-assembled microcapsules
[0078] The self-assembled microcapsules obtained in Example 10 were added to 293T cells (purchased from ATCC, #CRL-3216). After 24 hours, the cells were fixed with paraformaldehyde, the cell nuclei were stained with DAPI, and the expression of EGFP was observed under a laser confocal microscope, showing that 293T cells were bright green, demonstrating that EGFP-mRNA was well expressed in 293T cells.
[0079] Example 16: Application of non-interfacial self-assembled microcapsules
[0080] Human ovarian cancer A2780 paclitaxel-resistant cells A2780 / PTX (purchased from Nanjing Keygene Biotechnology, #KG635) were plated in a 96-well plate (10,000 cells per well), and the self-assembled microcapsules obtained in Example 6 were added to the 96-well plate. After 24 hours, paclitaxel injection was added at a concentration of 0.1-5 μmol / L. After 48 hours of culture, the inhibitory effect of the self-assembled microcapsules on the cells was detected using a CCK-8 kit. The results showed that after the human ovarian cancer A2780 paclitaxel-resistant cells were treated with the self-assembled microcapsules, the half-inhibitory concentration (IC50) of the cells to paclitaxel decreased from 8.5 μmol / L to 1.2 μmol / L ( Figure 8 ).
[0081] Example 17: Application of non-interfacial self-assembled microcapsules
[0082] Human ovarian cancer A2780 paclitaxel-resistant cells A2780 / PTX (purchased from Nanjing Keygene Biotechnology, #KG635) were plated in a 96-well plate (10,000 cells per well), and the self-assembled microcapsules obtained in Example 7 were added to the 96-well plate. After 24 hours, paclitaxel injection was added at a concentration of 0.1-5 μmol / L. After 48 hours of culture, the inhibitory effect of the self-assembled microcapsules on the cells was detected using a CCK-8 kit. The results showed that after the human ovarian cancer A2780 paclitaxel-resistant cells were treated with the self-assembled microcapsules, the half-inhibitory concentration (IC50) of the cells to paclitaxel decreased from 8.5 μmol / L to 1.5 μmol / L ( Fig. 9 ).
[0083] Example 18: Application of non-interfacial self-assembled microcapsules
[0084] Human ovarian cancer A2780 paclitaxel-resistant cells A2780 / PTX (purchased from Nanjing Keygene Biotechnology, #KG635) were lysed with sodium dodecyl sulfate (SDS) lysis buffer, and cell membranes were collected by high-speed centrifugation. DNA was then extracted using a DNA extraction kit (purchased from Qianggen Biotechnology).
[0085] 400 mg of DPPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of methanol and shaken at 60 ° C until completely dispersed. The extracted DNA was dispersed in the matrix gel, the mixture was mixed with 0.75 mL of matrix gel, and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing cell membranes. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules (artificial cells) were obtained, and artificial cells were prepared using the above method and used in subsequent immune experiments.
[0086] Example 19: Application of non-interfacial self-assembled microcapsules
[0087] Sodium dodecyl sulfate (SDS) lysis buffer was used to lyse human leukemia K562 adriamycin-resistant cells K562 / ADR (purchased from Nanjing Keygene Biotechnology, #KG301), and cell membranes were collected by high-speed centrifugation. DNA was then extracted using a DNA extraction kit (purchased from Qianggen Biotechnology).
[0088] 400 mg of DSPE-PEG-DTPA and 200 μL of polyethoxylated castor oil were dissolved in 0.5 mL of methanol and shaken at 60 °C until completely dispersed. The extracted DNA was dispersed in the matrix gel, the mixture was mixed with 0.75 mL of matrix gel, and then 3 mL of calcium chloride solution (60 mg / mL) was added. The mixture was then transferred to 20 mL of 1-bromoheptafluorooctane and shaken at room temperature for 30 minutes until it became a uniform and stable emulsion. The 1-bromoheptafluorooctane solution was then transferred to an aqueous solution containing cell membranes. Finally, after removing 1-bromoheptafluorooctane, self-assembled microcapsules (artificial cells) were obtained, and artificial cells were prepared using the above method and used in subsequent immune experiments.
[0089] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A method for preparing non-interface self-assembled microcapsules, comprising the following steps: (a) dissolving a polymer chelating agent and a cosolvent in an organic solvent, heating and shaking until they are completely dispersed; (b) mixing the cooled organic solvent with the gel-forming macromolecules; (c) after mixing, transferring to a solution containing metal ions for chelation to obtain a viscous colloid; characterized in that it also includes the steps of: (d) transferring the viscous colloid into a perfluorocarbon solvent and shaking at room temperature until a uniform emulsion is formed to obtain gel microspheres; (e) transferring the gel microspheres into an aqueous solution containing lipid molecules and shaking to obtain lipid gel microspheres; (f) removing the perfluorocarbon compounds in the lipid gel microspheres to obtain non-interfacial self-assembled microcapsules, The lipid molecules in step (e) are one or more of phosphatidylglycerol phospholipids, phosphatidylcholine phospholipids, phosphatidylserine phospholipids, 1-palmitoyl-2-stearoyl phosphatidylcholine, phosphatidylethanolamine phospholipids, glycerophosphatidic acid phospholipids, soybean lecithin, lysophospholipids, 1,2-dioleoyloxy-3-(dimethylamino)propane, 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine, (2,3-dioleoyl-propyl)-trimethylamine, erythrocyte membrane and tumor cell membrane; The polymer chelating agent in step (a) is one or more of polyvinyl alcohol, polyacrylic acid, heparin, dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol-diethylenetriamine pentaacetic acid, distearoylphosphatidylethanolamine-polyethylene glycol-diethylenetriamine pentaacetic acid, dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol-ethylenediaminetetraacetic acid, and distearoylphosphatidylethanolamine-polyethylene glycol-ethylenediaminetetraacetic acid; The macromolecule capable of forming a gel in step (b) is matrigel.
2. The preparation method according to claim 1, characterized in that: The perfluorocarbon compound in step (d) is one or more of perfluoroalkanes, perfluoroalkyl carboxylic acids, perfluoroalkylamines, perfluorohalogenated alkanes, and 3M fluorinated liquid FC-40.
3. The preparation method according to claim 2, characterized in that: In the step (d), the perfluorocarbon compound is a perfluoroalkane such as perfluorohexane, perfluorocyclohexane or perfluoroheptane, the perfluoroalkyl carboxylic acid is perfluorobutyric acid, perfluorooctanoic acid or tridecafluoroheptanoic acid, the perfluoroalkylamine is perfluorotriethylamine, and the perfluorohalogenated alkane is 1-bromoheptafluorooctane or perfluorohexyl bromide.
4. The preparation method according to claim 1, characterized in that: The cosolvent in step (a) is one or more of disodium lauryl sulfosuccinate, disodium fatty alcohol polyoxyethylene ether (3) sulfosuccinate, disodium coconut oil monoethanolamide sulfosuccinate, Span, monolauryl phosphate, Tween, potassium monododecyl phosphate, potassium lauryl ether phosphate, coconut oil monoethanolamide, and polyethoxylated castor oil.
5. The preparation method according to claim 1, characterized in that: The metal ions in step (c) are one or more of calcium ions, magnesium ions, sodium ions, potassium ions and iron ions.
6. A method for preparing non-interfacial self-assembled microcapsules loaded with bioactive substances, wherein the non-interfacial self-assembled microcapsules are prepared by the preparation method according to any one of claims 1 to 5, characterized in that: The following steps are also included: A bioactive substance is added to the mixture obtained in step (a) and the self-assembled microcapsules obtained in step (f) are mixed with genes, wherein the bioactive substance is a chemical drug and the gene is one or more of a plasmid, siRNA, microRNA, piRNA, circleRNA and lncRNA.
7. A non-interface self-assembled microcapsule, characterized in that: The non-interface self-assembled microcapsules are prepared by the method described in any one of claims 1-5.
Citation Information
Patent Citations
Microcapsule-manufacturing process and microcapsules
CN104519990A
Chelated calcium self-assembling nano particle, and preparation method and application thereof
CN113209304A
Lipid-coated albumin-bound chemotherapeutic drug nanoparticles as well as preparation method and application thereof
CN113876737A
Metal-extractant-containing capsule and method for producing the same
JP2003183744A
Compositions and methods for delivery of biomacromolecule agents
US20210106538A1
